A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3K Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma.
Do you Qualify?
These questions require a yes answer to qualify.
Are you at least 18 years of age?
Have you been treated with at least 2 prior systemic therapies?
Are you willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue?
These questions require a no answer to qualify.
Do you have a history of central nervous system lymphoma?
Have you ever had treatment with Idelalisib, pan-PI3K Inhibitor or treatment with a Bruton's Tyrosine Kinase inhibitor, (e.g: Ibrutinib)?
Have you ever tested positive for Hep B or Hep C?
If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.